These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18127680)

  • 1. Inactivation of the receptor-destroying enzyme of V. cholerae by immune sera.
    BURNET FM
    Aust J Exp Biol Med Sci; 1949 Mar; 27(2):217-22. PubMed ID: 18127680
    [No Abstract]   [Full Text] [Related]  

  • 2. Tryptic inactivation of the receptor-destroying enzeme of V. cholerae and of the enzymic activity of influenza virus.
    STONE JD
    Aust J Exp Biol Med Sci; 1949 May; 27(3):229-44. PubMed ID: 18137174
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of disease and immunity in cholera: a review.
    Holmgren J; Svennerholm AM
    J Infect Dis; 1977 Aug; 136 Suppl():S105-12. PubMed ID: 197173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholera antitoxin titrations: a comparative study of fat-cell, ileal-loop, and rabbit-skin assays.
    Curlin CT; Mosley WH; Greenough WB
    J Infect Dis; 1973 Mar; 127(3):294-8. PubMed ID: 4734668
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.
    Glass RI; Svennerholm AM; Khan MR; Huda S; Huq MI; Holmgren J
    J Infect Dis; 1985 Feb; 151(2):236-42. PubMed ID: 3968450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of infection-derived immunity to cholera.
    Levine MM; Black RE; Clements ML; Cisneros L; Nalin DR; Young CR
    J Infect Dis; 1981 Jun; 143(6):818-20. PubMed ID: 7252264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGGLUTINATING, LETHAL TOXIN AND E1 TOR HAEMOLYSIN NEUTRALIZING POTENCY OF SERA IN CHOLERA.
    FELSENFELD O; NASUNIYA N; WATANABE Y; PENA A; DALE BN
    Bull World Health Organ; 1964; 30(6):833-44. PubMed ID: 14215189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the ELISA method for cholera toxin determination in Vibrio cholerae cultures].
    González-Bonilla C; Gutiérrez-Cogco L; Moguel-Pech L; Villanueva-Zamudio A
    Rev Latinoam Microbiol; 1994; 36(4):273-6. PubMed ID: 7701137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.
    Levine MM; Nalin DR; Craig JP; Hoover D; Bergquist EJ; Waterman D; Holley HP; Hornick RB; Pierce NP; Libonati JP
    Trans R Soc Trop Med Hyg; 1979; 73(1):3-9. PubMed ID: 442179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection afforded by anti-hemolysin against V. cholerae El Tor infection in experimental cholera.
    Chaicumpa W; Samrejrongroj P; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Jun; 11(2):294-301. PubMed ID: 7434081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of the receptor destroying enzyme of V. cholera (RDE) in guinea-pigs.
    FRENCH EL; ADA GL
    Aust J Exp Biol Med Sci; 1954 Apr; 32(2):165-76. PubMed ID: 13189834
    [No Abstract]   [Full Text] [Related]  

  • 15. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.
    Clements ML; Levine MM; Young CR; Black RE; Lim YL; Robins-Browne RM; Craig JP
    J Infect Dis; 1982 Apr; 145(4):465-73. PubMed ID: 7069227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology & molecular biology of Vibrio cholerae O139 Bengal.
    Albert MJ
    Indian J Med Res; 1996 Jul; 104():14-27. PubMed ID: 8783504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralisation of the new cholera toxin by antiserum against crude enterotoxin of cholera toxin gene-positive Vibrio cholerae 01 in rabbit ileal loop model.
    Saha S; Sanyal SC
    Indian J Med Res; 1989 May; 89():117-20. PubMed ID: 2777342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immune response to the 18-kDa outer-membrane antigen of Vibrio cholerae.
    Sciortino CV
    J Med Microbiol; 1993 Aug; 39(2):135-40. PubMed ID: 8345508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera.
    Ehara M; Ichinose Y; Iwami M; Utsunomiya A; Shimodori S; Kangethe SK; Neves BC; Supawat K; Nakamura S
    Microbiol Immunol; 1993; 37(9):679-88. PubMed ID: 7505875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemolytic Vibrio cholerae O1 that is sensitive to Mukerjee's cholera phage IV and the phage produced by the hemolytic vibrio lysogenized with the infection of Mukerjee's cholera phage IV.
    Iwanaga M; Nakamura S; Kuyyakanond T
    Microbiol Immunol; 1989; 33(8):609-18. PubMed ID: 2779469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.